The Briefing Room: Novartis in India, Generic Drugs, Bird Flu, Sleep Apnea

April 1, 2013 OneMedPlace Team 0

In case you missed it, Monday featured a number of interesting developments in the world of healthcare and life sciences. Most notably, a seemingly rare patent defeat may harm Novartis’ bottom line in India, but helps secure a mass population to a popular leukemia drug. India has emerged as a leading market for drug innovation, yet faces a crossroads — as legislation now protects what has become the largest generic drug market in the world. Additionally, we’re interested in some new developments in Chinese bird flu, sleep apnea, and sexual health in adolescents.